Risk stratification of childhood medulloblastoma in the molecular era

the current consensus

Vijay Ramaswamy, Marc Remke, Eric Bouffet, Simon Bailey, Steven C. Clifford, Francois Doz, Marcel Kool, Christelle Dufour, Gilles Vassal, Till Milde, Olaf Witt, Katja von Hoff, Torsten Pietsch, Paul A. Northcott, Amar Gajjar, Giles W. Robinson, Laetitia Padovani, Nicolas André, Maura Massimino, Barry Pizer & 5 others Roger Packer, Stefan Rutkowski, Stefan M. Pfister, Michael D. Taylor, Scott L. Pomeroy

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Historical risk stratification criteria for medulloblastoma rely primarily on clinicopathological variables pertaining to age, presence of metastases, extent of resection, histological subtypes and in some instances individual genetic aberrations such as MYC and MYCN amplification. In 2010, an international panel of experts established consensus defining four main subgroups of medulloblastoma (WNT, SHH, Group 3 and Group 4) delineated by transcriptional profiling. This has led to the current generation of biomarker-driven clinical trials assigning WNT tumors to a favorable prognosis group in addition to clinicopathological criteria including MYC and MYCN gene amplifications. However, outcome prediction of non-WNT subgroups is a challenge due to inconsistent survival reports. In 2015, a consensus conference was convened in Heidelberg with the objective to further refine the risk stratification in the context of subgroups and agree on a definition of risk groups of non-infant, childhood medulloblastoma (ages 3–17). Published and unpublished data over the past 5 years were reviewed, and a consensus was reached regarding the level of evidence for currently available biomarkers. The following risk groups were defined based on current survival rates: low risk (>90 % survival), average (standard) risk (75–90 % survival), high risk (50–75 % survival) and very high risk (

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalActa Neuropathologica
DOIs
Publication statusAccepted/In press - Apr 4 2016

Fingerprint

Medulloblastoma
Biomarkers
Gene Amplification
Clinical Trials
Neoplasm Metastasis

Keywords

  • Genomics
  • Group 3
  • Group 4
  • Medulloblastoma
  • Outcomes
  • p53
  • SHH
  • Subgroups
  • WNT

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Cellular and Molecular Neuroscience

Cite this

Ramaswamy, V., Remke, M., Bouffet, E., Bailey, S., Clifford, S. C., Doz, F., ... Pomeroy, S. L. (Accepted/In press). Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 1-11. https://doi.org/10.1007/s00401-016-1569-6

Risk stratification of childhood medulloblastoma in the molecular era : the current consensus. / Ramaswamy, Vijay; Remke, Marc; Bouffet, Eric; Bailey, Simon; Clifford, Steven C.; Doz, Francois; Kool, Marcel; Dufour, Christelle; Vassal, Gilles; Milde, Till; Witt, Olaf; von Hoff, Katja; Pietsch, Torsten; Northcott, Paul A.; Gajjar, Amar; Robinson, Giles W.; Padovani, Laetitia; André, Nicolas; Massimino, Maura; Pizer, Barry; Packer, Roger; Rutkowski, Stefan; Pfister, Stefan M.; Taylor, Michael D.; Pomeroy, Scott L.

In: Acta Neuropathologica, 04.04.2016, p. 1-11.

Research output: Contribution to journalArticle

Ramaswamy, V, Remke, M, Bouffet, E, Bailey, S, Clifford, SC, Doz, F, Kool, M, Dufour, C, Vassal, G, Milde, T, Witt, O, von Hoff, K, Pietsch, T, Northcott, PA, Gajjar, A, Robinson, GW, Padovani, L, André, N, Massimino, M, Pizer, B, Packer, R, Rutkowski, S, Pfister, SM, Taylor, MD & Pomeroy, SL 2016, 'Risk stratification of childhood medulloblastoma in the molecular era: the current consensus', Acta Neuropathologica, pp. 1-11. https://doi.org/10.1007/s00401-016-1569-6
Ramaswamy, Vijay ; Remke, Marc ; Bouffet, Eric ; Bailey, Simon ; Clifford, Steven C. ; Doz, Francois ; Kool, Marcel ; Dufour, Christelle ; Vassal, Gilles ; Milde, Till ; Witt, Olaf ; von Hoff, Katja ; Pietsch, Torsten ; Northcott, Paul A. ; Gajjar, Amar ; Robinson, Giles W. ; Padovani, Laetitia ; André, Nicolas ; Massimino, Maura ; Pizer, Barry ; Packer, Roger ; Rutkowski, Stefan ; Pfister, Stefan M. ; Taylor, Michael D. ; Pomeroy, Scott L. / Risk stratification of childhood medulloblastoma in the molecular era : the current consensus. In: Acta Neuropathologica. 2016 ; pp. 1-11.
@article{7417e1d728944171b2fe0a2bc9c88030,
title = "Risk stratification of childhood medulloblastoma in the molecular era: the current consensus",
abstract = "Historical risk stratification criteria for medulloblastoma rely primarily on clinicopathological variables pertaining to age, presence of metastases, extent of resection, histological subtypes and in some instances individual genetic aberrations such as MYC and MYCN amplification. In 2010, an international panel of experts established consensus defining four main subgroups of medulloblastoma (WNT, SHH, Group 3 and Group 4) delineated by transcriptional profiling. This has led to the current generation of biomarker-driven clinical trials assigning WNT tumors to a favorable prognosis group in addition to clinicopathological criteria including MYC and MYCN gene amplifications. However, outcome prediction of non-WNT subgroups is a challenge due to inconsistent survival reports. In 2015, a consensus conference was convened in Heidelberg with the objective to further refine the risk stratification in the context of subgroups and agree on a definition of risk groups of non-infant, childhood medulloblastoma (ages 3–17). Published and unpublished data over the past 5 years were reviewed, and a consensus was reached regarding the level of evidence for currently available biomarkers. The following risk groups were defined based on current survival rates: low risk (>90 {\%} survival), average (standard) risk (75–90 {\%} survival), high risk (50–75 {\%} survival) and very high risk (",
keywords = "Genomics, Group 3, Group 4, Medulloblastoma, Outcomes, p53, SHH, Subgroups, WNT",
author = "Vijay Ramaswamy and Marc Remke and Eric Bouffet and Simon Bailey and Clifford, {Steven C.} and Francois Doz and Marcel Kool and Christelle Dufour and Gilles Vassal and Till Milde and Olaf Witt and {von Hoff}, Katja and Torsten Pietsch and Northcott, {Paul A.} and Amar Gajjar and Robinson, {Giles W.} and Laetitia Padovani and Nicolas Andr{\'e} and Maura Massimino and Barry Pizer and Roger Packer and Stefan Rutkowski and Pfister, {Stefan M.} and Taylor, {Michael D.} and Pomeroy, {Scott L.}",
year = "2016",
month = "4",
day = "4",
doi = "10.1007/s00401-016-1569-6",
language = "English",
pages = "1--11",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Risk stratification of childhood medulloblastoma in the molecular era

T2 - the current consensus

AU - Ramaswamy, Vijay

AU - Remke, Marc

AU - Bouffet, Eric

AU - Bailey, Simon

AU - Clifford, Steven C.

AU - Doz, Francois

AU - Kool, Marcel

AU - Dufour, Christelle

AU - Vassal, Gilles

AU - Milde, Till

AU - Witt, Olaf

AU - von Hoff, Katja

AU - Pietsch, Torsten

AU - Northcott, Paul A.

AU - Gajjar, Amar

AU - Robinson, Giles W.

AU - Padovani, Laetitia

AU - André, Nicolas

AU - Massimino, Maura

AU - Pizer, Barry

AU - Packer, Roger

AU - Rutkowski, Stefan

AU - Pfister, Stefan M.

AU - Taylor, Michael D.

AU - Pomeroy, Scott L.

PY - 2016/4/4

Y1 - 2016/4/4

N2 - Historical risk stratification criteria for medulloblastoma rely primarily on clinicopathological variables pertaining to age, presence of metastases, extent of resection, histological subtypes and in some instances individual genetic aberrations such as MYC and MYCN amplification. In 2010, an international panel of experts established consensus defining four main subgroups of medulloblastoma (WNT, SHH, Group 3 and Group 4) delineated by transcriptional profiling. This has led to the current generation of biomarker-driven clinical trials assigning WNT tumors to a favorable prognosis group in addition to clinicopathological criteria including MYC and MYCN gene amplifications. However, outcome prediction of non-WNT subgroups is a challenge due to inconsistent survival reports. In 2015, a consensus conference was convened in Heidelberg with the objective to further refine the risk stratification in the context of subgroups and agree on a definition of risk groups of non-infant, childhood medulloblastoma (ages 3–17). Published and unpublished data over the past 5 years were reviewed, and a consensus was reached regarding the level of evidence for currently available biomarkers. The following risk groups were defined based on current survival rates: low risk (>90 % survival), average (standard) risk (75–90 % survival), high risk (50–75 % survival) and very high risk (

AB - Historical risk stratification criteria for medulloblastoma rely primarily on clinicopathological variables pertaining to age, presence of metastases, extent of resection, histological subtypes and in some instances individual genetic aberrations such as MYC and MYCN amplification. In 2010, an international panel of experts established consensus defining four main subgroups of medulloblastoma (WNT, SHH, Group 3 and Group 4) delineated by transcriptional profiling. This has led to the current generation of biomarker-driven clinical trials assigning WNT tumors to a favorable prognosis group in addition to clinicopathological criteria including MYC and MYCN gene amplifications. However, outcome prediction of non-WNT subgroups is a challenge due to inconsistent survival reports. In 2015, a consensus conference was convened in Heidelberg with the objective to further refine the risk stratification in the context of subgroups and agree on a definition of risk groups of non-infant, childhood medulloblastoma (ages 3–17). Published and unpublished data over the past 5 years were reviewed, and a consensus was reached regarding the level of evidence for currently available biomarkers. The following risk groups were defined based on current survival rates: low risk (>90 % survival), average (standard) risk (75–90 % survival), high risk (50–75 % survival) and very high risk (

KW - Genomics

KW - Group 3

KW - Group 4

KW - Medulloblastoma

KW - Outcomes

KW - p53

KW - SHH

KW - Subgroups

KW - WNT

UR - http://www.scopus.com/inward/record.url?scp=84962148685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962148685&partnerID=8YFLogxK

U2 - 10.1007/s00401-016-1569-6

DO - 10.1007/s00401-016-1569-6

M3 - Article

SP - 1

EP - 11

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

ER -